A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy

Targeted Therapy
DOI: 10.1016/j.cclet.2024.109658 Publication Date: 2024-02-23T17:08:34Z